News - Eli Lilly


Current filters:

Eli Lilly

Popular Filters

40 to 64 of 207 results

Lilly acquires rights to Hutchison MediPharma cancer drug candidate

Lilly acquires rights to Hutchison MediPharma cancer drug candidate


Hutchison MediPharma, an R&D company majority owned by China’s Chi-Med, has entered into a licensing,…

Asia-PacificEli LillyfruquintinibHutchison MediPharmaLicensingOncologyPharmaceutical

Lilly reveals strong pipeline as it seeks to recover from reaching patent cliff

Lilly reveals strong pipeline as it seeks to recover from reaching patent cliff


Eli Lilly hopes to launch new medicines to treat unmet patient needs in an aim to return the company…

Eli LillyFinancialNorth AmericaPharmaceutical

Lilly’s ramucirumab significantly improves overall survival in advanced gastric cancer patients


US pharma major Eli Lilly (NYSE: LLY) has announced positive results from the Phase III REGARD trial…

Eli LillyOncologyPharmaceuticalramucirumabResearch

Mixed Phase III results with Lilly’s ramucirumab

Mixed Phase III results with Lilly’s ramucirumab


US drug major Eli Lilly has announced top-line results from a global Phase III study of ramucirumab in…

Eli LillyNorth AmericaOncologyPharmaceuticalramucirumabResearch

Geropharm to invest $45 million in Russian insulin production

Geropharm to invest $45 million in Russian insulin production


Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for…

DiabetesEli LillyEuropeFinancialGeropharmNovo NordiskPharmaceuticalProductionSanofi

Eli Lilly and Oxford University to fund three-year study into IBD


US drug major Eli Lilly (NYSE: LLY) has entered a partnership with Oxford University, UK, to fund a three-year…

Eli LillyEuropeGastro-intestinalsPharmaceuticalResearch

Novo Nordisk falls on loss of two US contracts


Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September…

Bristol-Myers SquibbDiabetesEli LillyMarkets & MarketingNorth AmericaNovo NordiskNovoLogPharmaceuticalVictoza

Pre-treatment with prasugrel - more risk, no benefit: ACCOAST


In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Zealand and Lilly to work together on type 2 diabetes and obesity therapies


Denmark's Zealand Pharma (Nasdaq OMX: ZEAL) has announced an exclusive peptide drug R&D collaboration…

DiabetesEli LillyGlobalPharmaceuticalResearchZealand Pharma

Eli Lilly latest to become embroiled in China bribery allegations


In the ongoing allegations of bribery and corruption by multinational drugmakers in China, US pharma…

Asia-PacificEli LillyLegalMarkets & MarketingPharmaceutical

NICE holds second consultation on Alimta for lung cancer maintenance


The UK's drugs watchdog the National Institute of Health and Care Excellence (NICE) is holding a second…

AlimtaEli LillyEuropeOncologyPharmaceuticalRegulation

Positive Ph III data for Trajenta in elderly type 2 diabetes patients


Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Eli Lilly's investigational sNSCLC drug meets Ph III endpoint


US drug major Eli Lilly's (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company…

BiotechnologyBristol-Myers SquibbEli LillynecitumumabOncologyPharmaceuticalResearch

Drug developed by UCSF researcher continues to show promise in type 1 diabetes


Teplizumab, an experimental drug designed to block the advance of type 1 diabetes in its earliest stages…

DiabetesEli LillyPharmaceuticalResearchteplizumab

TVM Life Science Ventures invests in Ixchelsis


Canada-based TVM Life Science Ventures VII has announced the fund's second investment, with Ixchelsis…

Eli LillyFinancialIX-01IxchelsisMen's HealthPfizerPharmaceuticalResearch

Boehringer Ingelheim and Eli Lilly launch linagliptin trial


German family-owned drug major Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) have enrolled…

Boehringer IngelheimDiabetesEli LillyEuropelinagliptinPharmaceuticalResearch

Adocia re-acquires exclusive rights to insulin analog from US drug major


French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Transition in new licensing deal with Eli Lilly


Canada's Transition Therapeutics (TSX: TTH) has entered an exclusive licensing of worldwide rights to…

Anti-Arthritics/RheumaticsEli LillyLicensingPharmaceuticalTransition TherapeuticsTT-601

Eli Lilly records higher than expected earnings in 2nd-qtr results


US drug major Eli Lilly's (NYSE: LLY) recorded higher than expected earnings as growth in key products…

AlimtaCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraZyprexa

US and European Rxing decisions on metastatic colorectal cancer


The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study


Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

40 to 64 of 207 results

Back to top